Simulation results for different scenarios of the <i>hmb</i> model described in the main text. by Brian C. O’Meara (8872658)

“…Model 1 is a constant rate; models 2 and 3 are increasing and decreasing rates with increased time, respectively; model 4 is a sine wave with a periodicity of 26 million years. …”

Supplementary Material for: ISPAD Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring by Tauschman M. (20458178)

“…A greater recognition of the importance of ongoing education and training for both health professionals and families in CGM use, including data interpretation, to ensure successful adoption and to optimize outcomes. 3.Updated information on CGM systems, technical aspects, and key features to guide device suitability and inform individual choice. 4.Increased evidence concerning CGM benefits for decreasing diabetic ketoacidosis (DKA) and severe hypoglycemic events; and improving quality of life in children and adolescents with T1D. 5.Recent developments concerning practical considerations associated with CGM utilization, encompassing topics such as exercise, skin concerns and use in telemedicine.…”

Comparative Study of Agricultural Wastes Utilization in Cementitious Composites by Marcin Małek (20597985)

“…Furthermore, corncobs showed an increase in most of mechanical properties but only up to 10 wt.% ratio and after that ratio a drop in value was noted. Similar trends to the ones presented in mechanical tests were noted during thermal properties tests. …”

Comparison of DSIMC generating co-cultures in the second week of incubation on days 9, 12 and 14. by Nils Ågren (21474419)

“…(b) The NK population (CD3-CD16 + CD56 + fraction of all CD45 + , here shown as a fraction of initial number on day 0) decreased linearly over time (n = 3). …”

PDLB - Balance Sheet by Nguyen Linh (19516642)

“…It built out management capabilities for a much larger bank, and is currently seeing decreasing Q/Q non-interest cost, while assets and interest income are growing nicely.…”

Discriminating wake vs. NREM sleep from individual spike train measures. by Fabiano Baroni (234173)

“…<p>A: Univariate decoding accuracies for one recording for each MSTM of the core set of 46 MSTMs. …”

Dataset and README file for paper from Denarie et al. by Marie-Emma Denarié (22670696)

“…Si-based defences are rapidly deployed, but it is unclear whether levels of Si defence affect herbivore performance linearly (i.e. increasing levels of Si continue to decrease performance), or whether resistance is only achieved above certain threshold levels.…”

Data Sheet 1_Qifuyin alleviates anxiety and depression in 3×Tg-AD mice by modulating neuroendocrine function.zip by Tianhao Yu (8120651)

“…Studies have shown that 3×Tg-AD mice, a classical animal model of AD, exhibit anxiety and depression-like behaviors characteristic of BPSD.…”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). …”